Double Allogenic Mesenchymal Stem Cells Transplantations Could Not Enhance Therapeutic Effect Compared with Single Transplantation in Systemic Lupus Erythematosus

The clinical trial of allogenic mesenchymal stem cells (MSCs) transplantation for refractory SLE patients has shown significant safety and efficacy profiles. However, the optimum frequency of the MSCs transplantation (MSCT) is unknown. This study was undertaken to observe whether double transplantat...

Full description

Bibliographic Details
Main Authors: Wang, Dandan, Akiyama, Kentaro, Zhang, Huayong, Yamaza, Takayoshi, Li, Xia, Feng, Xuebing, Wang, Hong, Hua, Bingzhu, Liu, Bujun, Xu, Huji, Chen, Wanjun, Shi, Songtao, Sun, Lingyun
Format: Online
Language:English
Published: Hindawi Publishing Corporation 2012
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3399403/
id pubmed-3399403
recordtype oai_dc
spelling pubmed-33994032012-07-24 Double Allogenic Mesenchymal Stem Cells Transplantations Could Not Enhance Therapeutic Effect Compared with Single Transplantation in Systemic Lupus Erythematosus Wang, Dandan Akiyama, Kentaro Zhang, Huayong Yamaza, Takayoshi Li, Xia Feng, Xuebing Wang, Hong Hua, Bingzhu Liu, Bujun Xu, Huji Chen, Wanjun Shi, Songtao Sun, Lingyun Clinical Study The clinical trial of allogenic mesenchymal stem cells (MSCs) transplantation for refractory SLE patients has shown significant safety and efficacy profiles. However, the optimum frequency of the MSCs transplantation (MSCT) is unknown. This study was undertaken to observe whether double transplantations of MSCs is superior to single transplantation. Fifty-eight refractory SLE patients were enrolled in this study, in which 30 were randomly given single MSCT, and the other 28 were given double MSCT. Patients were followed up for rates of survival, disease remission, and relapse, as well as transplantation-related adverse events. SLE disease activity index (SLEDAI) and serologic features were evaluated. Our results showed that no remarkable differences between single and double allogenic MSCT were found in terms of disease remission and relapse, amelioration of disease activity, and serum indexes in an SLE clinical trial with more than one year followup. This study demonstrated that single MSCs transplantation at the dose of one million MSCs per kilogram of body weight was sufficient to induce disease remission for refractory SLE patients. Hindawi Publishing Corporation 2012 2012-07-09 /pmc/articles/PMC3399403/ /pubmed/22829849 http://dx.doi.org/10.1155/2012/273291 Text en Copyright © 2012 Dandan Wang et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Wang, Dandan
Akiyama, Kentaro
Zhang, Huayong
Yamaza, Takayoshi
Li, Xia
Feng, Xuebing
Wang, Hong
Hua, Bingzhu
Liu, Bujun
Xu, Huji
Chen, Wanjun
Shi, Songtao
Sun, Lingyun
spellingShingle Wang, Dandan
Akiyama, Kentaro
Zhang, Huayong
Yamaza, Takayoshi
Li, Xia
Feng, Xuebing
Wang, Hong
Hua, Bingzhu
Liu, Bujun
Xu, Huji
Chen, Wanjun
Shi, Songtao
Sun, Lingyun
Double Allogenic Mesenchymal Stem Cells Transplantations Could Not Enhance Therapeutic Effect Compared with Single Transplantation in Systemic Lupus Erythematosus
author_facet Wang, Dandan
Akiyama, Kentaro
Zhang, Huayong
Yamaza, Takayoshi
Li, Xia
Feng, Xuebing
Wang, Hong
Hua, Bingzhu
Liu, Bujun
Xu, Huji
Chen, Wanjun
Shi, Songtao
Sun, Lingyun
author_sort Wang, Dandan
title Double Allogenic Mesenchymal Stem Cells Transplantations Could Not Enhance Therapeutic Effect Compared with Single Transplantation in Systemic Lupus Erythematosus
title_short Double Allogenic Mesenchymal Stem Cells Transplantations Could Not Enhance Therapeutic Effect Compared with Single Transplantation in Systemic Lupus Erythematosus
title_full Double Allogenic Mesenchymal Stem Cells Transplantations Could Not Enhance Therapeutic Effect Compared with Single Transplantation in Systemic Lupus Erythematosus
title_fullStr Double Allogenic Mesenchymal Stem Cells Transplantations Could Not Enhance Therapeutic Effect Compared with Single Transplantation in Systemic Lupus Erythematosus
title_full_unstemmed Double Allogenic Mesenchymal Stem Cells Transplantations Could Not Enhance Therapeutic Effect Compared with Single Transplantation in Systemic Lupus Erythematosus
title_sort double allogenic mesenchymal stem cells transplantations could not enhance therapeutic effect compared with single transplantation in systemic lupus erythematosus
description The clinical trial of allogenic mesenchymal stem cells (MSCs) transplantation for refractory SLE patients has shown significant safety and efficacy profiles. However, the optimum frequency of the MSCs transplantation (MSCT) is unknown. This study was undertaken to observe whether double transplantations of MSCs is superior to single transplantation. Fifty-eight refractory SLE patients were enrolled in this study, in which 30 were randomly given single MSCT, and the other 28 were given double MSCT. Patients were followed up for rates of survival, disease remission, and relapse, as well as transplantation-related adverse events. SLE disease activity index (SLEDAI) and serologic features were evaluated. Our results showed that no remarkable differences between single and double allogenic MSCT were found in terms of disease remission and relapse, amelioration of disease activity, and serum indexes in an SLE clinical trial with more than one year followup. This study demonstrated that single MSCs transplantation at the dose of one million MSCs per kilogram of body weight was sufficient to induce disease remission for refractory SLE patients.
publisher Hindawi Publishing Corporation
publishDate 2012
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3399403/
_version_ 1611543799270473728